Breaking News
Get 50% Off 0
Get a powerful boost to your portfolio: August's freshest AI-picked stocks
Pick Stocks with AI
Close

Genprex Inc (GNPX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Genprex's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.231 0.000    0.00%
01/08 - Closed. Currency in USD
After Hours
0.239
+0.008
+3.463%
0:41:22 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,178,184
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.220 - 0.236
Genprex 0.231 0.000 0.00%

Genprex Inc Company Profile

 
Get an in-depth profile of Genprex Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

15

Equity Type

ORD

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patient populations with unmet medical needs. The company’s technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. The company’s lead product candidate, Reqorsa gene therapy (quaratusugene ozeplasmid), for the treatment of non-small and small cell lung cancer. It is also developing diabetes gene therapy, a novel infusion process that uses an adeno-associated virus vector to deliver Pdx1 and MafA genes directly to the pancreatic duct; GPX-002 for Type 1 diabetes transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body’s immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has license agreement from the University of Pittsburgh of the Commonwealth System of Higher Education (University of Pittsburgh) multiple technologies relating to the development of a gene therapy product for both Type 1 and Type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Contact Information

Address 3300 Bee Cave Road Suite 650-227
Austin, 78746
United States
Phone 877 774 4679
Fax -

Top Executives

Name Age Since Title
Shu Kam Mok 65 - Member of Scientific & Medical Advisory Board
Pasi Antero Janne - - Member of Scientific & Medical Advisory Board
George Simon - - Member of Scientific & Medical Advisory Board
Ryan M. Confer 43 2016 President, CEO, CFO & Director
Jack A. Roth - - Chairman of Scientific & Medical Advisory Board
Michael Morse - 2021 Member of Clinical Advisory Board
Jose Antonio Moreno Toscano 52 2020 Independent Non-Executive Chairman
Brent M. Longnecker 69 2020 Independent Director
George K. Gittes - 2020 Member of Scientific Advisory Board
James E. Rothman 74 2012 Strategic Advisor to the Board of Directors
William R. Wilson 75 2020 Independent Director
George E. Peoples 62 2021 Member of Clinical Advisory Board
Andrew B. Becker - 2021 Member of Clinical Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GNPX Comments

Write your thoughts about Genprex Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email